GC Corp.
Financials
Valuation Metrics
GC Corp.'s Market Cap is ₩4680B. At end of 2025 it was ₩7710B. Ranked #488 of 2,421 in KR market (top 20%), #307 of 781 on KOSPI (top 39%), #54 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 468.03B KRW | KR#488/2,421 Sec#54/231 |
| Revenue | 2.49T KRW | KR#220/2,421 Sec#3/231 |
| Net Income | -151.13B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 4.07T KRW | KR#198/2,421 Sec#4/231 |
| Net Assets | 1.76T KRW | KR#204/2,421 Sec#7/231 |
| Employees | 155 | KR#1,297/2,421 Sec#105/231 |
| Value | ||
| P/B | 0.27x | KR#246/2,421 Sec#10/231 |
| P/S | 0.19x | KR#332/2,421 Sec#5/231 |
| EV/EBITDA | 60.59x | KR#1,391/2,421 Sec#91/231 |
| FCF Yield | -18.50% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -8.57% | KR#1,905/2,421 Sec#141/231 |
| ROA | -3.71% | KR#1,870/2,421 Sec#133/231 |
| Op. Margin | 1.17% | KR#1,489/2,421 Sec#103/231 |
| Revenue Growth | 9.57% | KR#928/2,421 Sec#90/231 |
| Earnings Growth | -168.39% | KR#1,221/2,421 Sec#81/231 |
| Financial Health | ||
| Debt Ratio | 130.71% | KR#1,796/2,421 Sec#201/231 |
| Total Debt | 1.37T KRW | KR#166/2,421 Sec#3/231 |
| FCF | -86.57B KRW | KR#2,125/2,421 Sec#210/231 |
| Cash | 79.66B KRW | KR#551/2,421 Sec#27/231 |
| Current Ratio | 0.96x | KR#1,772/2,421 Sec#175/231 |
| Net Debt/EBITDA | 44.44x | KR#1,476/2,421 Sec#103/231 |
| Dividend | ||
| Div. Yield | 3.14% | KR#609/2,421 Sec#27/231 |
| Div. Growth | -40.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -38.29% | KR#1,791/2,421 Sec#147/231 |
| 1M Return | -3.80% | KR#1,683/2,421 Sec#132/231 |
| From 52W High | -46.59% | KR#1,233/2,421 Sec#92/231 |
| 1Y MDD | -47.35% | KR#873/2,421 Sec#74/231 |
| Trading | ||
| Volume | 28,951 shares | KR#1,398/2,421 Sec#138/231 |
| Trading Value | 280.1M KRW | KR#1,145/2,421 Sec#116/231 |
| Foreign Own. | 8.20% | KR#543/2,421 Sec#46/231 |
| Per Share | ||
| EPS | -3,106 KRW | KR—/2,421 Sec—/231 |
| BPS | 36,253 KRW | KR#323/2,421 Sec#19/231 |
Company Info
Established in 1967 and headquartered in Yongin, Gyeonggi, Green Cross Holdings transitioned into a holding company in 2001. It oversees a total of 56 domestic and international corporate affiliates, led by Green Cross, primarily in biotechnology and healthcare. The company performs holding company roles such as management strategy and investment asset portfolio management, while actual business operations are handled by its subsidiaries. In 2025, it expanded its business scope by acquiring ABO Holdings to enter the US blood center business and consolidating 15 new companies including Bibros.